Prot #CA209-914: A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Project: Research project

Project Details

StatusActive
Effective start/end date10/9/17 → 10/9/23

Funding

  • Bristol-Myers Squibb Company (Prot #CA209-914)